Hemoccult ® SENSA® Products Hemoccult ® SENSA® Products
Increased Clinical Sensitivity and Improved Readablity.
 

Hemoccult SENSA Test
 

The Hemoccult SENSA test is a rapid, convenient and qualitative method for detecting fecal occult blood which may be indicative of gastrointestinal disease. It is not a test for colorectal cancer or any other specific disease.

Hemoccult SENSA has been proven to give the highest clinical sensitivity readings (92% for colorectal cancer)1,2, helping significantly in the early detection of pre-cancerous adenomas and colorectal cancers. Hemoccult SENSA has a more intense blue reaction, providing better readability than regular Hemoccult and other FOBTs.

Highest clinical sensitivity readings (92%)

Improved readability, intense blue reaction

14-day on-slide stability

Hemoccult SENSA Product Instructions (859k)
   

Product Effectiveness
 
The detection of occult blood in stool using Hemoccult SENSA, a more sensitive and readable test than regular Hemoccult, is a highly effective method for detecting bleeding associated with colorectal cancer and adenomas.

Prospective, randomized controlled clinical trials extending for up to 18 years have demonstrated that the Hemoccult products are effective in detecting occult blood in stool as an early indication colorectal cancer.

In clinical trials that enrolled over 339,000 individuals, mortality from colorectal cancer was reduced up to 33% when fecal occult blood tests were performed annually3-5 and 15-21% when performed biennially6. The program sensitivity for detecting colorectal cancer when Hemoccult was performed annually was 90%.7,8

Hemoccult SENSA Single Slides are convenient for use when single fecal specimens are collected for routine in-office gastrointestinal screening.

Hemoccult II SENSA Slides
are designed so patients can collect serial specimens at home from bowel movements over three days. After the patient prepares the Hemoccult II SENSA test, it may be returned in person or by mail (using the Hemoccult Mailing Pouch) to the laboratory, hospital or medical office for developing and interpretation.

The Hemoccult SENSA tests consist of two main components:


1.

Hemoccult SENSA Slides (Test Cards) containing guaiac paper

2.


Hemoccult SENSA Developer, a developing solution containing a stabilized mixture of less than 4.2% hydrogen peroxide and 80% denatured ethyl alcohol and enhancer in an aqueous solution.

Polyps and cancer may bleed intermittently. Hemoccult II SENSA triple slide products are designed so patients can collect serial specimens over three days. This increases the probability of detecting hidden blood from polyps and cancer.
   

Hemoccult SENSA Product Links
 
   
 

If you would like free samples or have a representative call you please contact:

1-800-877-6242 or 650-845-3526, or email us at askpcd@beckman.com

   

Footnotes:

1. Data on file, Product Development department, Beckman Coulter, Inc., Primary Care Diagnostics (formerly SmithKline Diagnostics).

2. Baker, J., et al.: "Readability and sensitivity of two guaiac-based fecal occult blood tests," Gastroenterol. 94(5):A5, 1988.

3. Hardcastle, J.D., et al.: "Randomised controlled trial of faecal-occult-blood screening for colorectal cancer," Lancet. 348:1471-1477, 1996.

4. Kronborg, O., et al.: "Randomised study of screening for colorectal cancer with faecal-occult-blood test," Lancet. 348:1467-1471, 1996.

5. Mandel, J.S., et al.: "Reducing mortality from colorectal cancer by screening for fecal occult blood," N Eng J Med. 328:1365-1371, 1993.

6. Mandel, J.S., et al.: "Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood," J Natl Cancer Inst. 91:434-437, 1999.

7. Ederer, F., et al.: "Fecal occult blood screening in the Minnesota Study:Role of chance detection of lesions," JNatl Cancer Inst.89:1423-1428, 1997.

8. Church, T.R., et al.: "Fecal occult blood screening in the Minnesota Study: Sensitivity of the screening test," J Natl Cancer Inst. 91:1440-1448, 1997.